Publications

Found 326 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
2018
Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E et al..  2018.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.. Cancer Discov. 8(12):1632-1653.
2017
Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.
Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.
Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov. 7(5):506-521.
Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.
Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.
Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLeah B, A Van den Heuvel PJ, Lev A, Garnett MJ, McDermott U et al..  2017.  Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.. PLoS One. 12(8):e0180541.
Jiang Y, Ortega-Molina A, Geng H, Ying H-Y, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X et al..  2017.  CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.. Cancer Discov. 7(1):38-53.
Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick A, Elemento O.  2017.  Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.. Cancer Res. 77(8):1818-1830.
Béguelin W, Rivas MA, Fernandez MTCalvo, Teater M, Purwada A, Redmond D, Shen H, Challman MF, Elemento O, Singh A et al..  2017.  EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.. Nat Commun. 8(1):877.
Reichel JB, McCormick J, Fromm JR, Elemento O, Cesarman E, Roshal M.  2017.  Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma.. J Vis Exp. (124)
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Carty M, Zamparo L, Sahin M, González A, Pelossof R, Elemento O, Leslie CS.  2017.  An integrated model for detecting significant chromatin interactions from high-resolution Hi-C data.. Nat Commun. 8:15454.
Mendoza A, Fang V, Chen C, Serasinghe M, Verma A, Muller J, V Chaluvadi S, Dustin ML, Hla T, Elemento O et al..  2017.  Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells.. Nature. 546(7656):158-161.
Mendoza A, Fang V, Chen C, Serasinghe M, Verma A, Muller J, V Chaluvadi S, Dustin ML, Hla T, Elemento O et al..  2017.  Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells.. Nature. 546(7656):158-161.
Mendoza A, Fang V, Chen C, Serasinghe M, Verma A, Muller J, V Chaluvadi S, Dustin ML, Hla T, Elemento O et al..  2017.  Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells.. Nature. 546(7656):158-161.
Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJirau, Wei Y, Duong J et al..  2017.  Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.. Clin Cancer Res. 23(12):3084-3096.
Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017
Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6
Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, Verma A, Bareja R, Chen Z, Scognamiglio T et al..  2017.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.. Elife. 6
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.